Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2018

May 11, 2018

SELL
$27.95 - $45.04 $380,762 - $613,579
-13,623 Closed
0 $0
Q4 2017

Feb 13, 2018

BUY
$35.44 - $63.76 $482,799 - $868,602
13,623
13,623 $511,000

Others Institutions Holding PRTA

About PROTHENA CORP PUBLIC LTD CO


  • Ticker PRTA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 46,922,800
  • Market Cap $685M
  • Description
  • Prothena Corporation plc, a late-stage clinical company, focuses on discovery and development of novel therapies for life-threatening diseases in the United States. The company is involved in developing Birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a human...
More about PRTA
Track This Portfolio

Track Landscape Capital Management, L.L.C. Portfolio

Follow Landscape Capital Management, L.L.C. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Landscape Capital Management, L.L.C., based on Form 13F filings with the SEC.

News

Stay updated on Landscape Capital Management, L.L.C. with notifications on news.